Catecholamine treatment for shock—equally good or bad?
- 31 August 2007
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 370 (9588), 636-637
- https://doi.org/10.1016/s0140-6736(07)61317-8
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Specificity of catecholamine-induced growth in Escherichia coli O157:H7, Salmonella enterica and Yersinia enterocoliticaFEMS Microbiology Letters, 2007
- Catecholamines: physiological immunomodulators during health and illness.Current Medicinal Chemistry, 2006
- Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shockCritical Care Medicine, 2004
- Stimulation of Staphylococcus epidermidis growth and biofilm formation by catecholamine inotropesThe Lancet, 2003
- Norepinephrine Inhibits Energy Metabolism of Human Peripheral Blood Mononuclear Cells via Adrenergic ReceptorsBioscience Reports, 2001
- The Mammalian Neuroendocrine Hormone Norepinephrine Supplies Iron for Bacterial Growth in the Presence of Transferrin or LactoferrinJournal of Bacteriology, 2000
- The Effects of β 1 -Blockade on Oxidative Metabolism and the Metabolic Cost of Ventricular Work in Patients With Left Ventricular DysfunctionCirculation, 2000
- Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia.JCI Insight, 1996
- RETRACTED ARTICLE: Alterations in circulating vasoactive substances in the critically ill —a comparison between survivors and non-survivorsIntensive Care Medicine, 1995
- Importance of Free Fatty Acids as a Determinant of Myocardial Oxygen Consumption and Myocardial Ischemic Injury during Norepinephrine Infusion in DogsJCI Insight, 1974